Cellular polyamine depletion for cancer treatment is hindered by compensatory uptake. ATP13A3, not ATP13A2, is the key polyamine importer affected by DFMO. Antizyme inhibits uptake by ATP13A3, suggesting a targetable strategy for cancer therapy.
Assay for NBD-labeled lipid uptake in HeLa-CDC50A-OE cells includes seeding, transfection, and flow cytometry to measure flippase construct activity, enabling quantitative assessment of lipid uptake.
